Pharmaceuticals, Biotechnology and Life Sciences
– Trial results to be submitted for presentation at upcoming medical meeting –BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN)...
As part of a collaborative working agreement between United Lincolnshire Hospitals NHS Trust and pharmaceutical company Boehringer Ingelheim, a new cardio-diabetic outpatient service has been launched to help reduce recurring heart attacks in people with diabetes.
AiCuris Anti-infective Cures AG has received milestone payments in the amount of EUR €30 million from its licensing partner MSD (Merck) after the U.S. FDA's approval for first-in-class antiviral agent...
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating 20th anniversary of FDA's approval of Botox Cosmetic.
The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) 21 consortium have published a joint work plan until 2023....
Sanofi has launched its Diversity, Equity & Inclusion (DE&I) Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors....
– Trial results to be submitted for presentation at upcoming medical meeting – BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Seagen Inc. (Nasdaq:…
As part of a collaborative working agreement between United Lincolnshire Hospitals NHS Trust and pharmaceutical company Boehringer Ingelheim, a new cardio-diabetic outpatient service has been launched to help reduce recurring heart attacks in people with diabetes.
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial.
Efficacy results, analyzed according to updated lymph node involvement classification, confirm clinical activity and favorable safety profile of lacutamab in…
PHAXIAM Provides Business and Financial UpdateFor the First Half of 2023 Conference call and webcast (English) on Monday, September 25,…
DURHAM, N.C., Sept. 21, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered…
REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to…
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial…
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America…
